BioCentury
ARTICLE | Clinical News

Aclerastide: Phase III discontinued

November 16, 2015 8:00 AM UTC

Derma said it will discontinue its 2 double-blind Phase III trials evaluating once-daily 0.03% DSC127 in patients with chronic, non-healing diabetic foot ulcers based on a pre-specified interim futili...